Skip to main content
TipRanks
Go Ultimate75% OFF

Acarix AB (ACARIX) AI Stock Analysis

3 Followers
SE:ACARIX

Acarix AB

(Nasdaq OMX AB:ACARIX)

Select Model
Rating:39Underperform
Price Target:SEK 0.16â–²(1.26% Upside)
Action:reiterated
Date:11/13/26

Acarix's highly suppressed score of 39 is primarily driven by substantial operational losses, persistent cash consumption, and a deeply negative valuation profile. While the company operates completely debt-free, the firmly bearish technical indicators across all major moving averages signal continued market skepticism and structural risks until a clear path to profitability is established.

Positive Factors
Improving Revenue and Gross MarginImproving revenue alongside a stronger gross margin indicates better commercial traction and unit economics. If sustained, this combination can increase the contribution from each sale, support reinvestment in the CADScor platform, and provide a foundation for eventual operating leverage.
Negative Factors
Severe Operating LossesExtremely negative operating and net margins show that current revenue remains far below the level needed to cover the company’s cost base. This weak profitability limits internally funded growth and leaves execution of commercialization plans highly sensitive to further revenue gains.

Acarix AB (ACARIX) vs. iShares MSCI Sweden ETF (EWD)

-50%-40%-30%-20%-10%0%10%20%30%SE:ACARIX-42.60%EWD+16.08%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
SEK 198.23M
Dividend Yield
―
Average Volume (3M)
1.44M
Price to Earnings (P/E)
-5.0
Beta (1Y)
0.10
Revenue Growth
40.61%
EPS Growth
32.63%
Country
Sweden
Employees
8
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Acarix AB Business Overview & Revenue Model

Company Description

Acarix AB (publ) is a medical technology company that develops and introduces diagnostic solutions for cardiovascular conditions to markets including Germany, Sweden, the Middle East, Switzerland, Austria, and globally. Their key product is the CADSc...

Acarix AB Financial Statement Overview

Summary

The company demonstrates top-line revenue growth and maintains a pristine, zero-debt balance sheet. However, this is heavily overshadowed by severe operational losses, a steep contraction in gross margins, and persistent cash burn that is eroding stockholders' equity.

Income Statement

35Negative

Balance Sheet

55Neutral

Cash Flow

30Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue9.73M7.36M6.20M6.24M5.82M3.76M
Gross Profit4.75M2.76M5.59M5.30M4.62M2.82M
EBITDA-33.84M-44.53M-62.63M-74.62M-73.78M-48.28M
Net Income-37.67M-48.09M-66.19M-77.84M-76.98M-51.80M
Balance Sheet
Total Assets41.41M48.33M80.76M62.88M69.48M118.60M
Cash, Cash Equivalents and Short-Term Investments21.00M18.27M53.99M35.15M11.31M15.81M
Total Debt0000251.00K523.00K
Total Liabilities3.43M10.16M5.06M11.00M17.66M18.06M
Stockholders Equity37.98M38.17M75.70M51.88M51.83M100.54M
Cash Flow
Free Cash Flow-24.04M-49.14M-64.25M-81.37M-75.02M-48.05M
Operating Cash Flow-35.79M-48.38M-63.33M-81.37M-74.87M-48.01M
Investing Cash Flow-233.00K-757.00K-920.00K0-151.00K-43.00K
Financing Cash Flow31.89M11.11M86.98M106.23M69.03M-164.00K

Acarix AB Technical Analysis

Technical Analysis SentimentNegative
Last Price0.16

Price Trends

50DMA0.19Negative
100DMA0.22Negative
200DMA0.25Negative

Market Momentum

MACD-0.01Negative
RSI33.45Neutral
STOCH36.24Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ACARIX, the sentiment is Negative. The current price of 0.16 is below the 20-day moving average (MA) of 0.17, below the 50-day MA of 0.19, and below the 200-day MA of 0.25, indicating a bearish trend. The MACD of -0.01 indicates Negative momentum. The RSI at 33.45 is Neutral, neither overbought nor oversold. The STOCH value of 36.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:ACARIX.

Acarix AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

SE:ACARIX against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:SECT.BSE:SECT.B78OutperformSEK 64.19B100.6130.26%0.70%13.94%5.70%
SE:SEZISE:SEZI55NeutralSEK 525.88M-5.39-35.44%―18.56%28.11%
SE:BACTI.BSE:BACTI.B53NeutralSEK 544.93M86.391.93%―-0.51%―
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SE:MNTCSE:MNTC51NeutralSEK 476.73M-25.25-15.00%―11.18%60.51%
SE:HEARTSE:HEART44NeutralSEK 135.11M-2.25-54.68%―――
SE:ACARIXSE:ACARIX39UnderperformSEK 198.23M-5.03-96.06%―40.61%32.63%

* Healthcare Sector Average

Performance Comparison

-50%-25%0%25%50%SE:ACARIXSE:SEZISE:BACTI.BSE:SECT.BSE:HEARTSE:MNTCDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SE:ACARIX and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SE:ACARIXAcarix AB0.16-0.11-41.76%
SE:SEZISenzime AB3.35-1.73-34.15%
SE:BACTI.BBactiguard Holding AB15.55-1.85-10.63%
SE:SECT.BSectra AB Class B329.0053.6019.46%
SE:HEARTScandinavian Real Heart AB15.901.4510.05%
SE:MNTCMentice AB16.953.1522.83%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 13, 2026